We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Eli Lilly has several exciting products in its pipeline, some of which are likely to earn approval in the next five years. Consider two of the company's leading candidates in weight loss ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

In a press release, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...

Like many pharma stocks, Eli Lilly (NYSE: LLY ... it's also pushing exciting weight loss candidates through the pipeline. So, there's room for smaller companies to succeed in the market, but ...